Shire's treatment for primary immunodeficiency wins FDA approval

(Reuters) - Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.